---
title: "Vor Biopharma (VOR) stock listing, news and investor profile"
url: "https://aibio.space/companies/vor-biopharma/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "Vor Biopharma Inc. (NASDAQ: VOR), United States. The directory classifies it as Biotechnology."
---

VOR Vor Biopharma Inc. NASDAQ · United States

# Vor Biopharma (VOR) news

Listings · 2025-07-10

## [Vor Bio names Sandy Mahatme CFO and grants 13,882,750 inducement RSUs](https://aibio.space/news/vor-bio-names-sandy-mahatme-cfo-grants-13-882-750-inducement-rsus/)

Vor Bio appointed Sandy Mahatme as chief financial officer and chief business officer effective July 9, 2025, and granted him 13,882,750 restricted stock units under Nasdaq's inducement rule. The release gives no share count or grant value to compare that award with.

## Latest Vor Biopharma news

1. 2025-06-26 Financings [Vor Bio licenses telitacicept from RemeGen for $45 million plus $80 million in warrants](https://aibio.space/news/vor-bio-licenses-telitacicept-remegen-45-million-plus-80-million/) Vor Bio agreed to pay RemeGen a $45 million upfront payment and $80 million in warrants for global rights to telitacicept, excluding Greater China. The only efficacy result cited is from a China Phase 3 study, and initial global results are expected in the first half of 2027.
2. 2025-05-08 Distress [Vor Biopharma winds down clinical operations, cuts 147 jobs and explores strategic alternatives](https://aibio.space/news/vor-biopharma-winds-down-clinical-operations-cuts-147-jobs-explores/) Vor estimates about $19.3 million in wind-down costs and plans to keep about 8 employees. Its chief financial officer and chief scientific officer were terminated without cause.

## Vor Biopharma at a glance

- **Ticker**: VOR

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Sep 30, 2026**: $481.6 million

### Related companies

- [Statera Biopharma](https://aibio.space/companies/statera-biopharma/) OTC: STAB
- [Foghorn Therapeutics](https://aibio.space/companies/foghorn-therapeutics/) NASDAQ: FHTX
- [Invivyd](https://aibio.space/companies/invivyd/) NASDAQ: IVVD
- [INmune Bio](https://aibio.space/companies/inmune-bio/) NASDAQ: INMB
- [Vaxart](https://aibio.space/companies/vaxart/) OTC: VXRT
- [Rapport Therapeutics](https://aibio.space/companies/rapport-therapeutics/) NASDAQ: RAPP
- [Intensity Therapeutics](https://aibio.space/companies/intensity-therapeutics/) NASDAQ: INTS
- [Elicio Therapeutics](https://aibio.space/companies/elicio-therapeutics/) NASDAQ: ELTX

### Also on NASDAQ

- [Genprex](https://aibio.space/companies/genprex/) GNPX
- [Q32 Bio](https://aibio.space/companies/q32-bio/) QTTB
- [Voyager Therapeutics](https://aibio.space/companies/voyager-therapeutics/) VYGR
- [ARS Pharmaceuticals](https://aibio.space/companies/ars-pharmaceuticals/) SPRY
- [Inogen](https://aibio.space/companies/inogen/) INGN
- [Valion Bio](https://aibio.space/companies/valion-bio/) VBIO

## Vor Biopharma annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | [$321.5 million](https://www.sec.gov/Archives/edgar/data/1817229/000119312526130451/) | [$93.3 million](https://www.sec.gov/Archives/edgar/data/1817229/000119312526130451/) |
| Net income (loss) | [-$696.0 million](https://www.sec.gov/Archives/edgar/data/1817229/000119312526130451/) | [-$116.9 million](https://www.sec.gov/Archives/edgar/data/1817229/000119312526130451/) |
| Cash from operations | [-$142.7 million](https://www.sec.gov/Archives/edgar/data/1817229/000119312526130451/) | [-$99.7 million](https://www.sec.gov/Archives/edgar/data/1817229/000119312526130451/) |
| Cash and equivalents | [$396.5 million](https://www.sec.gov/Archives/edgar/data/1817229/000119312526439905/) | [$81.9 million](https://www.sec.gov/Archives/edgar/data/1817229/000119312526130451/) |
| Short-term investments | [$58.7 million](https://www.sec.gov/Archives/edgar/data/1817229/000119312526439905/) | [$10.0 million](https://www.sec.gov/Archives/edgar/data/1817229/000119312526130451/) |

Latest balance sheet, Sep 30, 2026 (10-Q): cash and equivalents $79.0 million, plus short-term investments of $402.6 million, $481.6 million in all.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Vor Biopharma

What is the ticker symbol of Vor Biopharma?

Vor Biopharma Inc. trades under the ticker VOR on NASDAQ.

Where is Vor Biopharma listed?

Vor Biopharma Inc. is listed on NASDAQ.

What is the SEC CIK of Vor Biopharma?

The SEC Central Index Key (CIK) for Vor Biopharma Inc. is 1817229. Its filings are on SEC EDGAR.

How many shares does Vor Biopharma have outstanding?

59,162,294 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-11.

Which country or territory is Vor Biopharma listed under?

Our directory records Vor Biopharma Inc. under United States.

What does Vor Biopharma do?

Our directory classifies Vor Biopharma Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Vor Biopharma?

The ISIN recorded for Vor Biopharma Inc. is US9290332074.

Does aibio.space cover Vor Biopharma?

aibio.space lists Vor Biopharma Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Is Vor Biopharma profitable?

Vor Biopharma Inc. reported a net loss of $696.0 million for the fiscal year ended Dec 31, 2025, and used $142.7 million of cash in operations, per its annual report to the SEC.

How much does Vor Biopharma spend on research and development?

$321.5 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does Vor Biopharma have?

$481.6 million in cash and short-term investments at Sep 30, 2026, per its 10-Q.

What is the latest Vor Biopharma (VOR) stock news?

Our latest story on Vor Biopharma, dated Jul 10, 2025: "Vor Bio names Sandy Mahatme CFO and grants 13,882,750 inducement RSUs". Vor Bio appointed Sandy Mahatme as chief financial officer and chief business officer effective July 9, 2025, and granted him 13,882,750 restricted stock units under Nasdaq's inducement rule. The release gives no share count or grant value to compare that award with. [Source](https://aibio.space/news/vor-bio-names-sandy-mahatme-cfo-grants-13-882-750-inducement-rsus/).

What is Vor Biopharma's latest stock offering or financing news?

Our latest financing story, dated Jun 26, 2025: "Vor Bio licenses telitacicept from RemeGen for $45 million plus $80 million in warrants". Vor Bio agreed to pay RemeGen a $45 million upfront payment and $80 million in warrants for global rights to telitacicept, excluding Greater China. The only efficacy result cited is from a China Phase 3 study, and initial global results are expected in the first half of 2027. [Source](https://aibio.space/news/vor-bio-licenses-telitacicept-remegen-45-million-plus-80-million/).

How long will Vor Biopharma's cash last?

From our story of Jun 26, 2025: It also names Vor Bio's ability to continue as a going concern. [Source](https://aibio.space/news/vor-bio-licenses-telitacicept-remegen-45-million-plus-80-million/).

Is Vor Biopharma in financial distress?

Our latest distress story, dated May 8, 2025: "Vor Biopharma winds down clinical operations, cuts 147 jobs and explores strategic alternatives". Vor estimates about $19.3 million in wind-down costs and plans to keep about 8 employees. Its chief financial officer and chief scientific officer were terminated without cause. [Source](https://aibio.space/news/vor-biopharma-winds-down-clinical-operations-cuts-147-jobs-explores/).

## Investor discussion: Vor Biopharma

Members talk about Vor Biopharma (VOR). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Vor Biopharma, newest first. Each line links the filing it comes from.

1. 2026-10-30 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1817229/000119312526439975/d180165d424b5.htm)
2. 2026-04-27 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1817229/000119312526182106/d27587ds3.htm)
3. 2026-03-27 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1817229/000119312526127609/vor-ex99_1.htm)
4. 2026-01-29 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1817229/000119312526029364/d56846ds3.htm)
5. 2025-12-18 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1817229/000119312525324768/vor-ex99_1.htm)
6. 2025-11-10 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1817229/000119312525274350/d89411d424b5.htm)
7. 2025-09-24 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1817229/000119312525215602/d56908ds3.htm)
8. 2025-09-17 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1817229/000119312525205553/d945826d8k.htm)
9. 2025-08-27 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1817229/000119312525189133/d904071d424b5.htm)
10. 2025-08-27 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1817229/000119312525189169/d24419d8k.htm)
11. 2025-08-08 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1817229/000114036125029749/ny20051455x2_def14a.htm)
12. 2025-07-29 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1817229/000114036125027774/ny20051455x1_pre14a.htm)
13. 2025-07-10 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1817229/000119312525157638/d933755dex991.htm)
14. 2025-06-26 Financings Reported a financing. SEC Form 8-K (Items 1.01,1.02,3.02,5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1817229/000119312525147339/d27026dex991.htm)
15. 2025-05-23 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1817229/000119312525125833/d95113d8k.htm)
16. 2025-05-08 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1817229/000119312525115554/d924194dex991.htm)
17. 2025-04-25 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1817229/000119312525096692/d898205d8k.htm)
18. 2025-03-20 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1817229/000119312525059313/d829614ds3.htm)
19. 2025-01-21 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1817229/000119312525009566/d907390ds3.htm)
20. 2025-01-08 Financings Reported a financing. SEC Form 8-K (Items 5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1817229/000119312525003259/d861124dex991.htm)
21. 2024-12-27 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1817229/000119312524285627/d865206dex991.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:VOR on TradingView](https://www.tradingview.com/symbols/NASDAQ-VOR/).

## SEC filings and registration

- **SEC name**: Vor Biopharma Inc.

- **CIK**: 1817229

- **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836)

- **US tickers**: VOR (Nasdaq)

- **Fiscal year ends**: December 31

- **Filer category**: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

- **Business address**: 500 BOYLSTON STREET, BOSTON, MA, 02116

- **Phone**: 617-655-6580

- **Shares outstanding**: 59,162,294 as of 2026-08-06 (10-Q filed 2026-08-11)

### Recent filings (8-K and 6-K are the company's own announcements)

- [10-Q](https://www.sec.gov/Archives/edgar/data/1817229/000119312526343607/vor-20260630.htm) filed 2026-08-11
- [8-K](https://www.sec.gov/Archives/edgar/data/1817229/000119312526297454/vor-20260706.htm) filed 2026-07-07
- [8-K](https://www.sec.gov/Archives/edgar/data/1817229/000119312526269431/vor-20260611.htm) filed 2026-06-12
- [8-K](https://www.sec.gov/Archives/edgar/data/1817229/000119312526261661/vor-20260608.htm) filed 2026-06-08
- [10-Q](https://www.sec.gov/Archives/edgar/data/1817229/000119312526220689/vor-20260331.htm) filed 2026-05-13
- [S-3](https://www.sec.gov/Archives/edgar/data/1817229/000119312526182106/d27587ds3.htm) filed 2026-04-27
- [DEF 14A](https://www.sec.gov/Archives/edgar/data/1817229/000119312526181883/vor-20260423.htm) filed 2026-04-27
- [10-K](https://www.sec.gov/Archives/edgar/data/1817229/000119312526130451/vor-20251231.htm) filed 2026-03-30

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001817229), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Vor Biopharma Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker VOR, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Vor Biopharma Inc.

- **Ticker**: VOR

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Biotechnology

- **ISIN**: US9290332074

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-VOR/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/vor-biopharma/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Vor Biopharma (VOR) stock listing, news and investor profile", 2026-10-31, https://aibio.space/companies/vor-biopharma/